- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04786535
Efficacy of Uremic Toxins Clearance With Expanded Hemodialysis
Crossover Study of Three Groups Comparing the Efficacy of Uremic Toxins Clearance of Expanded Hemodialysis With Two Hemodialysis Membranes for Conventional Hemodialysis and Hemodiafiltration
The aim of this study is to quantify the B2-microglobulin reduction rate based on the type of extracorporeal therapy (ET) used: HDx (expanded hemodialysis), HDc (high-flux conventional hemodialysis), or HDF (hemodiafiltration).
And to compare the magnitude of the B2-microglobulin reduction rate based on the type of extracorporeal therapy (ET) used: HDx, HDc, or HDF
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A controlled, randomized, crossover clinical trial is planned to compare the magnitude of the B2-microglobulin reduction rate in three different extracorporeal therapies (ETs): HDc, HDx, and HDF.
The selection of study participants will be consecutive and for convenience
This study will be divided into six periods: three treatment periods (one for each therapy to be compared) and three of "washout" periods (interspersed between the treatment periods). The treatment periods will last four weeks (12 ET sessions, three per week) and will be preceded by a one-week washout period (three ET sessions)
After inclusion in the protocol, participants will be randomly assigned (with the help of a table of random numbers) to one of three ETs to be evaluated (HDc, HDx, or HDF). Afterwards, the first washout period will begin with high-flow conventional hemodialysis (HDc). At the end of the first washout period, the ET randomly assigned to one of three ETs to be evaluated (HDc, HDx, or HDF), following the sequence: Washout 1 -> Period 1 (HDC, HDx, or HDF) -> Washout 2 -> Period 2, etc.
For each period of ET, there will be two sampling times: baseline and final
Blood samples will be obtained through the arterial port of the extracorporeal circuit, at the beginning and at the end of the ET session. The "slow flow" method will be used (UF: 0 mL/min, Qd: 0 mL/min, and Qb: 100 mL/min, for 30 seconds, before extracting the sample from the arterial port) (24). Blood samples will be collected in dry tubes (without anticoagulant) and centrifuged for 10 minutes at 3,000 RPM. The supernatant will be divided into three aliquots and stored at -70°C for further processing.
To calculate sample size, the formula for a noninferiority study was used (Pharmaceutical statistics. 2016;15(1):80-9), which is detailed below:
n= ((r+1) (Z_(1-β)+Z_(1-α) )^2 σ^2)/(r((μ_A-μ_B )-d_NI )^2 )
The terms above, are substituted with values obtained from the publication of Kirsch et al. (Nephrol Dial Transplant. 2017 Jan 1;32(1):165-172) as follows:
Objective: Non-inferiority (Ho µA - µB ≤ -dNI vs. µA - µB > -dNI) Outcome: B2-microglobulin reduction rate. r: allocation ratio by group:1 beta: type II error (90% power):1.2816 alpha: type I error (level of significance 5%):1.960 (variance in the population):1.33 µA - µB (magnitude of the observed effect):80.6 - 78.5 = 2.1 dNI (non-inferiority limit): 3.5
n= ((1+1) (1.2816+1.960)^2 〖(1.33)〗^2)/(1((2.1)-3.5)^2 )= 19, the investigators estimate a 20 % loss in the follow-up , then investigators consider a sample size of n = 23 patients
The nominal variables will be presented in frequencies and proportions. Continuous numerical variables will be analyzed using the Kolmogorov-Smirnov "Z" test to determine their distribution. The results will be shown as the means ± standard deviation in case of normal distribution and as a median with minimum and maximum limits for variables with non-normal distribution.
The total serum concentration of the biochemical variables in general as well as the uremic toxins will be analyzed. Additionally, the reduction rate and purification of the uremic toxins will be analyzed.
The analyses of the inter- and intra-group differences will be performed using the one-way multiple comparisons (ANOVA) method. Post hoc analysis using the Bonferroni method will be used in cases where the groups present a normal distribution; otherwise, the Kruskal-Wallis method will be used. A result with a p < 0.05 will be considered significant
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Mexico City, Mexico, 14080
- Recruiting
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Over 18 years
- Anuric patients (residual urinary volume ≤ 100 mL/24 h)
- Intermittent chronic hemodialysis (three sessions per week, of 3.5 to 4 hours each)
- Without modification of their prescription in the last three months
- Functional arteriovenous fistula, indwelling vascular access (Qb ≥ 300 mL/min), or both
- Letter of acceptance to enter the protocol and a signed informed consent.
Exclusion Criteria:
- Under 18 years
- Active intake or intake in the last six months of immunosuppressants or systemic steroids
- Active autoimmune disease
- Evidence of active systemic infectious event at the time of inclusion or two weeks prior
- Diagnosis of neoplasia or active oncological disease
- Hypoalbuminemia (< 3.2 g/dL)
- Pregnancy or lactation
- Refusal to participate in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Hemodiafiltration
|
|
EXPERIMENTAL: Expanded hemodialysis
|
|
EXPERIMENTAL: Conventional high-flux hemodialysis
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
B2-microglobulin reduction rate
Time Frame: At final of each period of ET (4 weeks)
|
B2-microglobulin reduction rate based on the type of extracorporeal therapy (ET) used: HDx, HDc, or HDF.
|
At final of each period of ET (4 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urea reduction rate
Time Frame: At final of each period of ET (4 weeks)
|
Urea reduction rate based on the type of extracorporeal therapy (ET) used: HDx, HDc, or HDF.
|
At final of each period of ET (4 weeks)
|
Phosphorus reduction rate
Time Frame: At final of each period of ET (4 weeks)
|
Phosphorus reduction rate based on the type of extracorporeal therapy (ET) used: HDx, HDc, or HDF.
|
At final of each period of ET (4 weeks)
|
Interleukin 6 reduction rate
Time Frame: At final of each period of ET (4 weeks)
|
Interleukin 6 reduction rate based on the type of extracorporeal therapy (ET) used: HDx, HDc, or HDF.
|
At final of each period of ET (4 weeks)
|
P-cresol reduction rate
Time Frame: At final of each period of ET (4 weeks)
|
P-cresol reduction rate based on the type of extracorporeal therapy (ET) used: HDx, HDc, or HDF.
|
At final of each period of ET (4 weeks)
|
Tumor necrosis factor-a reduction rate
Time Frame: At final of each period of ET (4 weeks)
|
Tumor necrosis factor-a reduction rate based on the type of extracorporeal therapy (ET) used: HDx, HDc, or HDF.
|
At final of each period of ET (4 weeks)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ricardo Correa-Rotter, MD, Head Departament of Nephrology and Mineral Metabolism,
Publications and helpful links
General Publications
- Zickler D, Schindler R, Willy K, Martus P, Pawlak M, Storr M, Hulko M, Boehler T, Glomb MA, Liehr K, Henning C, Templin M, Trojanowicz B, Ulrich C, Werner K, Fiedler R, Girndt M. Medium Cut-Off (MCO) Membranes Reduce Inflammation in Chronic Dialysis Patients-A Randomized Controlled Clinical Trial. PLoS One. 2017 Jan 13;12(1):e0169024. doi: 10.1371/journal.pone.0169024. eCollection 2017.
- Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR, Krieter DH. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017 Jan 1;32(1):165-172. doi: 10.1093/ndt/gfw310. Erratum In: Nephrol Dial Transplant. 2021 Jul 23;36(8):1555-1556.
- Belmouaz M, Diolez J, Bauwens M, Duthe F, Ecotiere L, Desport E, Bridoux F. Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules . Clin Nephrol. 2018 Jan;89 (2018)(1):50-56. doi: 10.5414/CN109133 .
- Ronco C. The Rise of Expanded Hemodialysis. Blood Purif. 2017;44(2):I-VIII. doi: 10.1159/000476012. Epub 2017 May 10.
- Ronco C, Marchionna N, Brendolan A, Neri M, Lorenzin A, Martinez Rueda AJ. Expanded haemodialysis: from operational mechanism to clinical results. Nephrol Dial Transplant. 2018 Oct 1;33(suppl_3):iii41-iii47. doi: 10.1093/ndt/gfy202.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REF.2937
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Renal Disease
-
Outset MedicalCompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on DialysisUnited States
-
University of Illinois at ChicagoWithdrawnObesity | End-Stage Renal Disease | Renal Disease, End-Stage | Renal Failure, End-StageUnited States
-
Bioconnect Systems, IncCompletedEnd-stage Renal Disease | End-stage Kidney DiseaseUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Changhai Hospital; Shanghai Zhongshan Hospital; RenJi Hospital; Ruijin Hospital; Shanghai... and other collaboratorsCompleted
-
Clinical Research Center for End Stage Renal Disease...Kyungpook National University Hospital; Medical Research Collaborating Center... and other collaboratorsActive, not recruitingEnd-Stage Renal DiseaseKorea, Republic of
-
Medtronic - MITGCompletedEnd-stage Renal DiseaseGermany
-
China Medical University HospitalUnknown
-
Guangdong Provincial Hospital of Traditional Chinese...Ministry of Science and Technology of the People´s Republic of ChinaUnknown
-
University of California, San FranciscoCompletedEnd-stage Renal DiseaseUnited States
-
Mark A. LumleyHenry Ford Health SystemCompleted
Clinical Trials on Hemodiafiltration
-
University of NottinghamFresenius Medical Care Deutschland GmbHCompletedMyocardial Perfusion | Other Postprocedural Cardiac Functional Disturbances
-
Chulalongkorn UniversityCompletedEnd-stage Renal DiseaseThailand
-
McGill University Health Centre/Research Institute...McGill University; Gambro Renal Products, Inc.UnknownEnd Stage Renal Disease | Sleep ApneaCanada
-
Ramathibodi HospitalArkom Nongnuch; Supawadee Suppadungsuk; Adisorn PathumarakRecruitingPrimary Outcome : Compare Percent CRP Reduction | Secondary Outcome : 30-day Mortality, Renal Recovery, Length of Hospital StayThailand
-
University Hospital, GhentGambro Corporate Research, SwedenCompletedChronic Renal FailureBelgium
-
Centre Hospitalier Universitaire de NīmesCompletedRenal Failure, AcuteFrance
-
University of Erlangen-Nürnberg Medical SchoolRenal Research InstituteCompletedChronic Kidney Disease Requiring Chronic DialysisGermany
-
Maimónides Biomedical Research Institute of CórdobaInstituto de Salud Carlos IIICompletedChronic Kidney Disease Requiring Chronic DialysisSpain
-
Seoul National University HospitalSamsung Medical Center; Seoul St. Mary's Hospital; Baxter Healthcare Corporation and other collaboratorsCompletedKidney Failure, Chronic | Renal DialysisKorea, Republic of
-
Amsterdam UMC, location VUmcB.Braun Avitum AG; Niercentrum aan de Amstel, Amstelveen, NetherlandsCompletedHemodialysis | End Stage Renal Disease (ESRD) | Diastolic Dysfunction | Hemodiafiltration | Intradialytic HypotensionNetherlands